NEW YORK (GenomeWeb) – Biocept said today that it has signed an in-network provider agreement for its Target Selector liquid biopsy platform with Wellmark Blue Cross Blue Shield in Iowa and South Dakota.
This is Biocept's third BCBS contract and enables cancer patients to access the company's testing services in network under their Wellmark health plans.
The Target Selector technology is designed to analyze circulating tumor cell and circulating tumor DNA biomarkers from a blood sample. Biocept offers tests for a variety of cancers including lung, breast, colorectal, gastric, skin, and prostate.
"The Wellmark contract marks another important milestone in our initiative to increase access for patients with Blue Cross Blue Shield to our Target Selector platform," Biocept President and CEO Michael Nall said in a statement. "In-network status with major health insurers reduces a barrier for patients diagnosed with cancer and their physicians to benefit from our proprietary and patented solutions. With this agreement in place, approximately 200 million patients have in-network access to our testing platform, with some members having access via multiple health plans."